
News & Publications
News
December 23, 2020
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
Press releasePublication
December 9, 2020
HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease
Cytotherapy
Publication
December 4, 2020
Re-examination of MAGE-A3 as a T-cell Therapeutic Target
Journal of ImmunotherapyPublication
November 9, 2020
A Multivariate, Quantitative Assay that Disentangles Key Kinetic Parameters of Primary Human T Cell Function In Vitro
PLOS ONE
Perspective
November 4, 2020
Cancer T-cell Therapy: Building the Foundation for a Cure
F1000Research
News
October 6, 2020
A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics
Press release
Publication
October 2, 2020
Engineered T Cells Directed at Tumors With Defined Allelic Loss
Molecular Immunology
Presentation
October 1, 2020
Engineered T Cells Directed at Tumors With Defined Allelic Loss
3rd Cell Therapies and Immunotherapy Conference
Poster
August 31, 2020
A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics
The Essential Protein Engineering & Cell Therapy Summit Virtual
Publication
August 5, 2020
Structure-function Relationships of Chimeric Antigen Receptors in Acute T Cell Responses to Antigen
Molecular Immunology
Publication
November 21, 2019
Single Variable Domains from the T Cell Receptor β Chain Function as Mono-and Bifunctional CARs and TCRs
Scientific Reports
News
November 5, 2019
Press release